NEW YORK (GenomeWeb News) — Transposagen Biopharmaceuticals said today that it has expanded its license for DNA transposon technology to cover nearly all commercial applications, including as a tool for drug and biomarker discovery.

The intellectual property for the transposon technology, called piggyBac, is jointly owned by the University of Notre Dame, the University of Florida, and the US Department of Agriculture.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.